Literature DB >> 19767635

NSF after Gadovist exposure: a case report and hypothesis of NSF development.

Helmut Wollanka1, Werner Weidenmaier, Cecylia Giersig.   

Abstract

So far no cases of nephrogenic systemic fibrosis (NSF) have been published on macrocyclical gadolinium-based contrast media (Gd-CM), assumed as low NSF risk CM due to their complex stability. In our haemodialysis-dependent patient, the first symptoms indicating NSF appeared about 16 months after the exposure to Gadovist, a macrocyclical Gd-CM, and 1 month after x-ray angiography with iodinated CM (Ultravist). This indicates that in addition to excretory renal failure and Gd-CM exposure, the loss of biosynthetic renal function could be essential for NSF development. A hypothesis of possible pathways involved in the development of NSF is presented.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19767635     DOI： 10.1093/ndt/gfp494

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


  13 in total

Review 1.  Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.

Authors:  Lesley J Scott
Journal:  Clin Drug Investig       Date:  2013-04       Impact factor: 2.859

2.  Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Authors:  Z Seidl; J Vymazal; M Mechl; M Goyal; M Herman; C Colosimo; M Pasowicz; R Yeung; B Paraniak-Gieszczyk; B Yemen; N Anzalone; A Citterio; G Schneider; S Bastianello; J Ruscalleda
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

3.  The extra miles on preventing nephrogenic systemic fibrosis.

Authors:  A Adhipatria P Kartamihardja; Yoshito Tsushima
Journal:  Quant Imaging Med Surg       Date:  2019-11

4.  Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.

Authors:  Zhitong Zou; Lin Ma
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

5.  Stability of MRI contrast agents in high-energy radiation of a 1.5T MR-Linac.

Authors:  Jihong Wang; Travis Salzillo; Yongying Jiang; Yuri Mackeyev; Clifton David Fuller; Caroline Chung; Seungtaek Choi; Neil Hughes; Yao Ding; Jinzhong Yang; Sastry Vedam; Sunil Krishnan
Journal:  Radiother Oncol       Date:  2021-06-03       Impact factor: 6.901

6.  Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.

Authors:  Jan Endrikat; Kai Vogtlaender; Susan Dohanish; Thomas Balzer; Josy Breuer
Journal:  Invest Radiol       Date:  2016-09       Impact factor: 6.016

7.  Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?

Authors:  M A Kirchin; V Lorusso; G Pirovano
Journal:  Br J Radiol       Date:  2015-02-04       Impact factor: 3.039

8.  Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study.

Authors:  Martin R Prince; Hae Giu Lee; Chang-Hee Lee; Sung Won Youn; In Ho Lee; Woong Yoon; Benqiang Yang; Haiping Wang; Jin Wang; Tiffany Ting-Fang Shih; Guo-Shu Huang; Jiing-Feng Lirng; Petra Palkowitsch
Journal:  Eur Radiol       Date:  2016-03-09       Impact factor: 5.315

9.  Prospective, randomized comparison of gadopentetate and gadobutrol to assess chronic myocardial infarction applying cardiovascular magnetic resonance.

Authors:  Andre Rudolph; Daniel Messroghli; Florian von Knobelsdorff-Brenkenhoff; Julius Traber; Johannes Schüler; Ralf Wassmuth; Jeanette Schulz-Menger
Journal:  BMC Med Imaging       Date:  2015-11-17       Impact factor: 1.930

10.  Section 4: Contrast-induced AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.